Skip to main content

Table 8 Lumpectomy and mastectomy frequencies in the Safety and Efficacy populations after study treatment (number of patients and percentage of respective analysis subset)

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

  Safety ITT PP
  N = 32 = 4 months (N = 14) > 4 months (N = 15) = 4 months (N = 14) > 4 months (N = 11)
  n (%) n (%) n (%) n (%) n (%)
Lumpectomy 22 (68.8%) 10 (71.4%) 12 (80.0%) 10 (71.4%) 8 (72.7%)
Mastectomy 9 (28.1%) 4 (28.6%) 3 (20.0%) 4 (28.6%) 3 (27.3%)
Missing data 1 (3.1%) -- -- -- --
Total 32 (100.0%) 14 (100.0%) 15 (100.0%) 14 (100.0%) 11 (100.0%)